C.P. Schröder

985 total citations
17 papers, 377 citations indexed

About

C.P. Schröder is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C.P. Schröder has authored 17 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C.P. Schröder's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Medical Imaging Techniques and Applications (3 papers). C.P. Schröder is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Medical Imaging Techniques and Applications (3 papers). C.P. Schröder collaborates with scholars based in Netherlands, Germany and Denmark. C.P. Schröder's co-authors include Elisabeth G.E. de Vries, Adrienne H. Brouwers, Bert van der Vegt, Frederike Bensch, Johan R. de Jong, Stefan Sleijfer, Marjolijn N. Lub–de Hooge, Geke A.P. Hospers, Steven de Jong and N. H. Mulder and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C.P. Schröder

16 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.P. Schröder Netherlands 9 179 138 90 62 57 17 377
Valentina Magri Italy 11 207 1.2× 56 0.4× 66 0.7× 63 1.0× 28 0.5× 28 345
Yaoxiong Xia China 13 122 0.7× 42 0.3× 139 1.5× 99 1.6× 16 0.3× 39 348
Evangelia Peponi Greece 9 87 0.5× 59 0.4× 145 1.6× 157 2.5× 15 0.3× 20 448
Eriseld Krasniqi Italy 10 197 1.1× 42 0.3× 93 1.0× 95 1.5× 22 0.4× 21 342
A. Fontana Switzerland 8 104 0.6× 104 0.8× 143 1.6× 169 2.7× 14 0.2× 10 421
Saya Jacob United States 11 226 1.3× 43 0.3× 89 1.0× 116 1.9× 18 0.3× 27 363
Sylvia Gruber Austria 12 110 0.6× 77 0.6× 67 0.7× 173 2.8× 26 0.5× 27 369
Sophie Brackrock Germany 7 84 0.5× 134 1.0× 137 1.5× 82 1.3× 35 0.6× 8 333
Bi-Yun Wang China 5 73 0.4× 41 0.3× 96 1.1× 67 1.1× 15 0.3× 6 253
Lars F. Norum Norway 7 58 0.3× 91 0.7× 141 1.6× 33 0.5× 15 0.3× 9 263

Countries citing papers authored by C.P. Schröder

Since Specialization
Citations

This map shows the geographic impact of C.P. Schröder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.P. Schröder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.P. Schröder more than expected).

Fields of papers citing papers by C.P. Schröder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.P. Schröder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.P. Schröder. The network helps show where C.P. Schröder may publish in the future.

Co-authorship network of co-authors of C.P. Schröder

This figure shows the co-authorship network connecting the top 25 collaborators of C.P. Schröder. A scholar is included among the top collaborators of C.P. Schröder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.P. Schröder. C.P. Schröder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Voort, Anna van der, C.P. Schröder, Astrid N. Scholten, et al.. (2024). 318TiP Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study. Annals of Oncology. 35. S347–S347.
3.
Heer, Ellen C. de, Christos E. Zois, Edward G. Bridges, et al.. (2023). Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research. 42(1). 143–143. 9 indexed citations
4.
Voorwerk, Leonie, Hugo M. Horlings, Inge Kemper, et al.. (2020). 135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer. Annals of Oncology. 31. S61–S61. 4 indexed citations
5.
Hoekstra‐Weebers, Josette E. H. M., et al.. (2019). Distress, problems, referral wish, and supportive health care use in breast cancer survivors beyond the first year after chemotherapy completion. Supportive Care in Cancer. 28(7). 3023–3032. 8 indexed citations
6.
Bensch, Frederike, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, et al.. (2018). 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. European Journal of Nuclear Medicine and Molecular Imaging. 45(13). 2300–2306. 104 indexed citations
7.
Bense, Rico D., Elisabeth G.E. de Vries, C.P. Schröder, & Rudolf S.N. Fehrmann. (2017). Higher expression of estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER+/HER2-breast cancer. Annals of Oncology. 28. v60–v60. 1 indexed citations
8.
Han, Sileny, Frédéric Amant, Elyce Cardonick, et al.. (2017). Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Research and Treatment. 168(2). 551–557. 28 indexed citations
9.
Venema, Clasina M., C.P. Schröder, Michel van Kruchten, et al.. (2017). Qualitative and quantitative analyses of F-18-FES and F-18-FDHT uptake in patients with metastatic breast cancer: an interobserver variability study. Data Archiving and Networked Services (DANS). 44. 1 indexed citations
10.
Lamberts, Laetitia E., C. Willemien Menke‐van der Houven van Oordt, Frederike Bensch, et al.. (2014). Pet-Imaging with 89Zr-Labeled Anti-Mesothelin (Msln) Antibody in Patients with Pancreatic Cancer (Pc) or Ovarian Cancer (Oc). Annals of Oncology. 25. iv562–iv562. 4 indexed citations
11.
Vries, Elisabeth G.E. de, Adrienne H. Brouwers, Geke A.P. Hospers, et al.. (2012). 15 Imaging Visualisation of Drug Target and Drug Effect. European Journal of Cancer. 48. 8–8. 2 indexed citations
12.
Schröder, C.P., Sue Chua, Charles Swanton, et al.. (2011). Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e11024–e11024. 21 indexed citations
13.
Kroep, Judith R., Sabine C. Linn, Epie Boven, et al.. (2010). Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.. PubMed. 68(9). 371–6. 13 indexed citations
14.
Munnink, Thijs H. Oude, Wouter B. Nagengast, Adrienne H. Brouwers, et al.. (2009). Molecular imaging of breast cancer. The Breast. 18. S66–S73. 74 indexed citations
15.
Schröder, C.P., G. Bea A. Wisman, Steven de Jong, et al.. (2001). Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. British Journal of Cancer. 84(10). 1348–1353. 85 indexed citations
16.
17.
Mühle, Christiane, et al.. (1995). Positionsgestell zur kinematischen Magnetresonanztomographie der Halswirbelsäule. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 162(3). 252–254. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valentina Magri Breakdown of academic impact, for papers by Yaoxiong Xia Breakdown of academic impact, for papers by Evangelia Peponi Breakdown of academic impact, for papers by Eriseld Krasniqi Breakdown of academic impact, for papers by A. Fontana Breakdown of academic impact, for papers by Saya Jacob Breakdown of academic impact, for papers by Sylvia Gruber Breakdown of academic impact, for papers by Sophie Brackrock Breakdown of academic impact, for papers by Bi-Yun Wang Breakdown of academic impact, for papers by Lars F. Norum
Rankless by CCL
2026